The introduction of tyrosine kinase inhibitors (TKIs) directed against EGFR, such as erlotinib, afatinib, and gefitinib, has improved the outlook for this subgroup of patients [5] and these drugs now represent standard first-line treatment for EGFR Mut+ NSCLC [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.